CRBN and plasma cell myeloma: Although our conclusion was obtained from multiple cell lines and two primary patient samples, we cannot completely rule out the possibility that CASP-8 inhibition might not have a significant influence on the treatment of certain myeloma cell lines or some patient samples when CASP-8, CRBN, or other component of the CRL4CRBN E3 ligase is not expressed or is mutated.